Other News To Note
Monday, April 18, 2011
Pozen Inc., of Chapel Hill, N.C., said the U.S. District Court for the Eastern District of Texas granted a preliminary injunction ordering Par Pharmaceutical Inc., of Woodcliff Lake, N.J., not to make, use, sell, offer to sell or import into the U.S. a generic version of Treximet (sumatriptan/naproxen sodium). Treximet is sold by Pozen's partner, London-based GlaxoSmithKline plc. The order was entered in connection with the patent infringement lawsuit pending among Pozen and a handful of generic firms.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.